Sign In
Buy CPRX
$31.28
+0.0100 (+0.0320%)
At Close: Jun 03, 2026
Catalyst Pharmaceuticals, Inc. (CPRX) Q2 2024 Earnings Call Transcript
01:30pm, Thursday, 08'th Aug 2024
Call End: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q2 2024 Earnings Conference Call August 08, 2024, 08:30 AM ET Company Participants Michael Kalb - Chief Financial Officer Richard Daly - Preside
Catalyst (CPRX) Rises as Q2 Earnings & Revenues Beat Estimates
10:45am, Thursday, 08'th Aug 2024
Catalyst (CPRX) gains as it reports strong second-quarter results, wherein earnings and revenues beat the Zacks Consensus Estimate, primarily driven by strong Firdapse sales.
Catalyst (CPRX) Reports Q2 Earnings: What Key Metrics Have to Say
09:30pm, Wednesday, 07'th Aug 2024
While the top- and bottom-line numbers for Catalyst (CPRX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare t
Catalyst Pharmaceutical (CPRX) Beats Q2 Earnings and Revenue Estimates
08:40pm, Wednesday, 07'th Aug 2024
Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.33 per share a year ago.
Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update
04:11pm, Wednesday, 07'th Aug 2024
Delivered Robust Revenue Performance, Fueled by Exceptional Commercial Execution and Early Success of the U.S. AGAMREE® Product Launch
CORAL GABLES, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, de
Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024
08:03am, Monday, 22'nd Jul 2024
The Company will Host a Conference Call and Webcast on Thursday, August 8, 2024, at 8:30 AM ET The Company will Host a Conference Call and Webcast on Thursday, August 8, 2024, at 8:30 AM ET
Why Is Catalyst (CPRX) Up 0.7% Since Last Earnings Report?
12:36pm, Friday, 07'th Jun 2024
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
01:41pm, Thursday, 30'th May 2024
CORAL GABLES, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev
Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024
08:03am, Tuesday, 28'th May 2024
CORAL GABLES, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev
2 Incredible Growth Stocks to Buy Hand Over Fist Right Now
08:00am, Wednesday, 15'th May 2024
Growth stocks have been steadily marching higher since the 2008 financial crisis. Even so, there are still plenty of compelling bargains in the space.
Catalyst's New CEO Has Big Ideas For The Small Biotech
09:30am, Friday, 10'th May 2024
Richard Daly has watched Catalyst Pharmaceuticals transform. Now, as the company's new CEO, he has some metamorphic ideas of his own.
Catalyst (CPRX) Q1 Earnings Beat, Firdapse Sales Drive Revenues
12:41pm, Thursday, 09'th May 2024
Catalyst (CPRX) reports first-quarter results, wherein earnings and revenues beat the Zacks Consensus Estimate, driven by strong Firdapse sales.
Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2024 Earnings Call Transcript
10:52am, Thursday, 09'th May 2024
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Michael Kalb - Chief Financial Officer Richard Daly - President and Chief Exe
Top 10% Biotech Stock Catalyst Pharma Doubles Wall Street's Profit Views
05:08pm, Wednesday, 08'th May 2024
Catalyst Pharmaceuticals doubled Wall Street's earnings expectations late Wednesday, and the biotech stock recovered from an earlier slide.
